Fresenius Kabi said it was committed to developing and marketing biosimilars, especially for autoimmune and oncology indications, as the injectables and infusion specialist inaugurated a biosimilars research and development center that its Fresenius Kabi SwissBioSim unit has built in Eysins, Switzerland. The German company recently took its first commercial step into the biosimilars arena by rolling out its Idacio adalimumab brand in several European countries.
Kabi said the center, in which the firm invested about €15m ($16m), would “intensify biosimilars research and development in the...